Warning: This security is no longer trading.
Exact Sciences completes $2.8B acquisition of Genomic Health
Genomic Health, Inc. (GHDX): Price and Financial Metrics
Genomic Health, Inc. (GHDX):
GET POWR RATINGS...
GHDX Stock Summary GHDX's current price/earnings ratio is 44.63, which is higher than 83.63% of US stocks with positive earnings. The price/operating cash flow metric for NA is higher than 85.42% of stocks in our set with a positive cash flow. Over the past twelve months, GHDX has reported earnings growth of 194.66%, putting it ahead of 93.48% of US stocks in our set. Stocks that are quantitatively similar to GHDX, based on their financial statements, market capitalization, and price volatility, are OMCL, OSIS, PCTY, QDEL, and SPSC.
GHDX Price/Volume Stats
Genomic Health, Inc. (GHDX) Company Bio
Genomic Health provides actionable genomic information to personalize cancer treatment decisions in the United States and internationally. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions. The company was founded in 2000 and is based in Redwood City, California.
GHDX Latest News Stream
All News Types
Loading, please wait...
GHDX Price Returns
Page generated in 0.7514 seconds.